Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspirational people in the life-sciences industry.
|
SAN DIEGO, Aug. 3, 2020 /PRNewswire/ --Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspirational people in the life-sciences industry.
Ms. Pelletier was recognized for her unwavering commitment to advancing the sexual and reproductive health of women and for her leadership role in Evofem's rapid growth and evolution. During her tenure as CEO, she has led the Company's transition to the public market, secured U.S. regulatory approval of Phexxi™ (lactic acid, citric acid and potassium bitartrate), the first and only non-hormonal, prescription contraceptive gel, and raised more than $400 million through multiple financing rounds. The Company is also advancing EVO100 into a Phase 3 clinical trial for the prevention of urogenital transmission of chlamydia and gonorrhea in women. "Saundra is a visionary leader whose compassion captures your attention, who inspires you to be more, and whose intellect changes your worldview," said Anne Marbarger, Executive Director at Padres Pedal the Cause. "Under Saundra's leadership, Evofem Biosciences is bringing to market innovative products that will fundamentally change women's health and drive gender parity during a time in history where it is particularly relevant." Ms. Pelletier was diagnosed with late-stage breast cancer in July 2018 and continued running Evofem while undergoing multiple surgeries and intensive chemotherapy. In addition to her roles as CEO and single mother of a 13-year-old son, she is also active in her community through such organizations as Padres Pedal the Cause. "I am honored to be recognized by PharmaVoice among such an accomplished group of individuals and am grateful to those who nominated me," said Ms. Pelletier. "As the CEO of a female-forward company committed to improving women's health, I am thrilled with the breadth of female leaders and diversity of talent reflected on this list. Together, we are innovating and advocating for new therapies, better care and improved outcomes, while also investing in the next generation of trailblazers, entrepreneurs and glass-ceiling breakers." PharmaVOICE Magazine released its annual list of the 100 most inspiring people in life sciences on August 1, identifying industry thought leaders and innovators who have made the biggest impact in their fields. About Phexxi™ (lactic acid, citric acid and potassium bitartrate) Vaginal Gel Important Safety Information What are the possible side effects of Phexxi? The most common side effects were vaginal burning, vaginal itching, vaginal yeast infection, urinary tract infection, vaginal area discomfort, bacterial vaginosis, and vaginal discharge. Women also reported genital discomfort, pain while urinating, and vaginal pain. Some male partners reported genital discomfort. What else should I know about using Phexxi? Contact your healthcare provider if you are experiencing severe genital irritation or discomfort or urinary tract symptoms. Avoid Phexxi if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi. Stop using Phexxi if you develop an allergic reaction. Please see full Prescribing Information for Phexxi, including Patient Information. Please report side effects by contacting Evofem Biosciences® toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About Evofem Biosciences, Inc. Forward-Looking Statements Contact Media
SOURCE Evofem Biosciences, Inc. |
||
Company Codes: NASDAQ-NMS:EVFM |
View original content to download multimedia:
